List of news related to Vanguard Group Inc:

Title: CVS Health Corporation $CVS Shares Bought by Asset Management One Co. Ltd.
URL: https://transcriptdaily.com/2025/10/25/cvs-health-corporation-cvs-shares-bought-by-asset-management-one-co-ltd.html
Time Published: 2025-10-26T03:03:21Z
Full Content:
Posted by Joseph Casey on Oct 25th, 2025 Asset Management One Co. Ltd. raised its position in CVS Health Corporation (NYSE:CVS – Free Report) by 7.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 551,705 shares of the pharmacy operator’s stock after acquiring an additional 37,350 shares during the period. Asset Management One Co. Ltd.’s holdings in CVS Health were worth $38,057,000 as of its most recent filing with the Securities & Exchange Commission. Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in CVS Health by 0.8% in the first quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator’s stock valued at $8,017,223,000 after acquiring an additional 969,027 shares in the last quarter. Dodge & Cox boosted its stake in CVS Health by 4.8% in the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after acquiring an additional 3,353,223 shares in the last quarter. Invesco Ltd. boosted its stake in CVS Health by 13.2% in the first quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock valued at $1,383,039,000 after acquiring an additional 2,375,764 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in CVS Health by 14.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator’s stock valued at $1,037,205,000 after acquiring an additional 1,942,886 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in CVS Health by 5.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator’s stock valued at $924,643,000 after acquiring an additional 728,924 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds. In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the transaction, the director owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.22% of the company’s stock. Shares of CVS Health stock opened at $81.95 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.80 and a quick ratio of 0.62. The firm has a fifty day moving average price of $75.57 and a 200 day moving average price of $68.67. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $83.52. The stock has a market cap of $103.94 billion, a PE ratio of 22.89, a price-to-earnings-growth ratio of 0.89 and a beta of 0.60. CVS Health (NYSE:CVS – Get Free Report) last issued its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The firm had revenue of $98.92 billion during the quarter, compared to analysts’ expectations of $94.87 billion. During the same quarter last year, the company posted $1.83 earnings per share. The firm’s revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current year. The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Thursday, October 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 3.2%. CVS Health’s payout ratio is presently 74.30%. Several research firms have recently commented on CVS. Morgan Stanley lifted their price objective on shares of CVS Health from $82.00 to $89.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 14th. Zacks Research downgraded shares of CVS Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th. Mizuho lifted their price objective on shares of CVS Health from $76.00 to $88.00 and gave the stock an “outperform” rating in a research note on Thursday, October 9th. Sanford C. Bernstein lifted their price objective on shares of CVS Health from $72.00 to $77.00 and gave the stock a “market perform” rating in a research note on Friday, September 5th. Finally, Wells Fargo & Company lifted their price objective on shares of CVS Health from $84.00 to $103.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average target price of $83.38. Get Our Latest Stock Report on CVS (Free Report) CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter. R Squared Ltd Has $342,000 Position in Wabtec $WAB Travel + Leisure (NYSE:TNL) Stock Price Expected to Rise, Barclays Analyst Says
--------------------------------------------------

Title: Sumitomo Mitsui Trust Group Inc. Sells 597,807 Shares of CVS Health Corporation $CVS
URL: https://www.dailypolitical.com/2025/10/25/sumitomo-mitsui-trust-group-inc-sells-597807-shares-of-cvs-health-corporation-cvs.html
Time Published: 2025-10-26T01:06:04Z
Full Content:
Posted by Jeff Wilder on Oct 25th, 2025 Sumitomo Mitsui Trust Group Inc. trimmed its position in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 17.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,897,620 shares of the pharmacy operator’s stock after selling 597,807 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.23% of CVS Health worth $199,878,000 as of its most recent filing with the Securities and Exchange Commission. Several other institutional investors and hedge funds have also bought and sold shares of CVS. Vanguard Group Inc. boosted its holdings in shares of CVS Health by 0.8% in the first quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator’s stock worth $8,017,223,000 after acquiring an additional 969,027 shares during the period. Dodge & Cox boosted its holdings in shares of CVS Health by 4.8% in the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after acquiring an additional 3,353,223 shares during the period. Invesco Ltd. boosted its holdings in shares of CVS Health by 13.2% in the first quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock worth $1,383,039,000 after acquiring an additional 2,375,764 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of CVS Health by 14.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator’s stock worth $1,037,205,000 after acquiring an additional 1,942,886 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of CVS Health by 5.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator’s stock worth $924,643,000 after acquiring an additional 728,924 shares during the period. 80.66% of the stock is owned by institutional investors. Shares of CVS Health stock opened at $81.95 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.80 and a quick ratio of 0.62. The business’s 50 day simple moving average is $75.57 and its two-hundred day simple moving average is $68.67. The stock has a market capitalization of $103.94 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 0.89 and a beta of 0.60. CVS Health Corporation has a one year low of $43.56 and a one year high of $83.52. CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.35. The business had revenue of $98.92 billion for the quarter, compared to analysts’ expectations of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that CVS Health Corporation will post 5.89 EPS for the current year. The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s payout ratio is presently 74.30%. In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director directly owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.22% of the company’s stock. CVS has been the subject of a number of analyst reports. Barclays raised their price target on CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a report on Thursday, September 4th. Morgan Stanley raised their price target on CVS Health from $82.00 to $89.00 and gave the company an “overweight” rating in a research report on Tuesday, October 14th. UBS Group increased their price objective on CVS Health from $79.00 to $96.00 and gave the company a “buy” rating in a research report on Friday. Cantor Fitzgerald reiterated an “overweight” rating and set a $78.00 price objective on shares of CVS Health in a research report on Tuesday, August 26th. Finally, Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a research report on Sunday, September 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $83.38. Check Out Our Latest Analysis on CVS Health (Free Report) CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report). Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter. Carrera Capital Advisors Acquires New Stake in Kenvue Inc. $KVUE Sumitomo Mitsui Trust Group Inc. Boosts Stake in DoorDash, Inc. $DASH
--------------------------------------------------

Title: Opinion: B.C.’s voodoo vaping legislation
URL: https://financialpost.com/opinion/bc-voodoo-vaping-legislation
Time Published: 2025-10-24T10:00:08Z
Description: Smart public health policy would simplify life for legal producers and sellers of non-tobacco nicotine sources. B.C. is doing the opposite
--------------------------------------------------

Title: 24/7 Market News: VENU Hitting All the Right Notes and Scaling to Meet Record Demand
URL: https://www.globenewswire.com/news-release/2025/10/23/3172049/0/en/24-7-Market-News-VENU-Hitting-All-the-Right-Notes-and-Scaling-to-Meet-Record-Demand.html
Time Published: 2025-10-23T12:40:00Z
Full Content:
October 23, 2025 08:40 ET | Source: 24/7 Market News and VENU 24/7 Market News and VENU DENVER, Oct. 23, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that VENU (NYSE American: VENU), a growing operator of premium hospitality and live entertainment venues across the U.S., has achieved a series of transformative milestones that position the company for accelerated national growth and long-term profitability. VENU’s recent performance underscores its ability to merge real estate, entertainment, and community impact into one unified, scalable business model. Over the past 60 days, VENU achieved $23 million in Luxe FireSuite sales, driving a 250% year-over-year increase and signaling unprecedented record investor demand. The company’s $5 billion development pipeline, with $1.3 billion currently under construction across Texas, Colorado, Oklahoma, and Georgia, is propelling VENU toward its goal of 40 venues by 2030, including 25 amphitheaters and 15 indoor complexes. The company’s Public-Private Partnership (PPP) model continues to be a powerful engine for expansion. By collaborating with local governments that fund or offset a significant portion of upfront development costs, including land, infrastructure, and site preparation, VENU converts what would typically be heavy debt into bookable assets, accelerating profitability and community return on investment. Currently, 38 municipalities are in active discussions to bring VENU entertainment campuses to their regions, with current projects, largely the first four amphitheaters, projected to create 4,700 jobs and drive $17.7 billion in economic impact over the next two decades. In less than three years, VENU has proven that innovation, ownership, and access can coexist in live entertainment. VENU’s model combines the stability of real estate with the emotional power of music and the results are speaking for themselves. VENU’s Luxe FireSuites, which offer investors fractional real estate ownership with an anticipated 11% cap rate, have already sold $163 million of the $334 million inventory across Tulsa, McKinney, and El Paso projects. The company anticipates 2025 FireSuite sales to double, supported by a national advertising campaign running through November 15 on FOX News, FOX Business, CNBC, Peacock, and Newsmax. Further bolstering momentum, Vanguard Group disclosed a position in VENU, reflecting increasing institutional confidence. The company’s blockchain-powered digital platform, launching in 2026, will tokenize ticketing and memberships, streamlining fan engagement and loyalty across 40 venues. Strategic partnerships with Tixr, Aramark Sports + Entertainment, Ryan LLC, Troy Aikman’s EIGHT Elite Light Beer, and Sands Investment Group provide operational strength, while VENU’s alliance with AEG Presents ensures top-tier touring and booking integration. With high-velocity sales and expanding institutional interest, VENU is positioned to capture a meaningful share of the $408.5 billion global music event market, redefining what it means to own, experience, and invest in live entertainment. Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com. For the full 24/7 Market News VENU report and in-depth insights, including analyst reports, visit: Read 24/7 Market News VENU Report/ Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services. About Venu Holding Corporation Venu Holding Corporation (NYSE American: VENU) is redefining the live entertainment landscape through a national network of premium amphitheaters powered by its Luxe FireSuites model. With partnerships like AEG and Aramark, and an active development pipeline of over $5 billion (including $1 billion underway), Venu is building the next generation of destination venues, where investors, fans, and artists come together in a hospitality-first experience. Through its innovative 40/40/20 financing model and integrated hospitality campuses, the company is building a national network of premium amphitheaters and entertainment destinations, targeting 40 venues by 2030. Its flagship Ford Amphitheater was nominated as Pollstar’s Best New Venue of 2024. About 24/7 Market News 24/7 Market News (24/7 MN) is a leading market news platform for public companies. As a pioneer in digital media, 24/7 MN is dedicated to the swift distribution of financial market news and information. 24/7 MN takes great pride in creating innovative public relations campaigns that help clients reach the target audience. 24/7 MARKET NEWS, INC (247) Disclaimer and DisclosurePAID EDITORIAL DISCLOSURE: 247MarketNews.com has been compensated $2,500 per week by MicroCap Strategies for ongoing press and editorial coverage of VENU. This is a paid editorial communication intended for informational purposes only. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information. CONTACT:24/7 Market NewsEditor@247marketnews.com Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. The construction of VENU’s (NYSE American: VENU) $350M Sunset Amphitheater McKinney is progressing on schedule, marking a major milestone VENU Holdings (NYSE American:VENU) is a real estate play that’s building the infrastructure for America’s next entertainment revolution
--------------------------------------------------

Title: Fixed Income Assets Management Industry Report 2025: Strategic Insights and Forecasts to 2030, Emerging Trends and Growth Opportunities
URL: https://www.globenewswire.com/news-release/2025/10/23/3171765/28124/en/Fixed-Income-Assets-Management-Industry-Report-2025-Strategic-Insights-and-Forecasts-to-2030-Emerging-Trends-and-Growth-Opportunities.html
Time Published: 2025-10-23T08:44:00Z
Full Content:
October 23, 2025 04:44 ET | Source: Research and Markets Research and Markets Dublin, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The "Fixed Income Assets Management - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Fixed Income Assets Management was valued at US$26.5 Trillion in 2024 and is projected to reach US$36.9 Trillion by 2030, growing at a CAGR of 5.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.Fixed income assets management plays a pivotal role in ensuring stability and income generation in investment portfolios, particularly during periods of market volatility. Fixed income instruments, such as government bonds, corporate bonds, and treasury securities, provide regular interest payments and principal protection, making them a reliable source of income for conservative investors. These assets are especially important in managing risk within diversified portfolios, as they typically perform inversely to equities during market downturns. Institutional investors, including pension funds, insurance companies, and wealth managers, heavily rely on fixed income management to meet their long-term financial obligations. In addition, the ability of fixed income strategies to generate consistent returns makes them appealing to retirees and income-focused investors.How Is the Fixed Income Market Segmented?Key asset types include government bonds, municipal bonds, corporate bonds, and mortgage-backed securities. Each type offers different risk profiles, returns, and tax benefits. Issuers vary from government entities and municipalities to corporations, with sovereign bonds generally considered the safest due to their government backing. Geographically, North America, Europe, and Asia-Pacific lead in terms of market size, with emerging markets offering higher yields but carrying additional risks. Investment strategies are tailored to client needs, ranging from conservative income generation to more aggressive strategies that seek to capitalize on market opportunities in high-yield or emerging market debt.What Technological Advancements Are Impacting Fixed Income Assets Management?Technological innovations are transforming fixed income management by enhancing trade execution, portfolio management, and risk assessment. The integration of artificial intelligence (AI) and machine learning algorithms is enabling asset managers to analyze vast datasets, identify trends, and make more informed investment decisions. The adoption of electronic trading platforms has improved liquidity and transparency in bond markets, providing faster and more efficient trade execution. In addition, big data analytics are helping managers assess market risks more accurately, while fintech solutions are streamlining compliance and reporting processes. These technological advancements are helping asset managers optimize portfolio performance and adapt to a rapidly changing market environment.What Factors Are Driving Growth in the Fixed Income Assets Management Market?The growth in the fixed income assets management market is driven by several factors, including rising demand for income-generating investments, increasing institutional allocations to bonds, and the growing popularity of sustainable and ESG-linked fixed income products. The aging global population is driving demand for fixed income assets as retirees seek stable income streams to fund their retirement. Moreover, heightened geopolitical uncertainties and economic volatility are pushing investors toward safe-haven assets like government bonds. Technological advancements in AI and data analytics are also improving the precision and efficiency of fixed income strategies, while the growing focus on green bonds and ESG considerations is expanding the market for socially responsible investments.Report ScopeThe report analyzes the Fixed Income Assets Management market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below. Key Insights: Report Features: Some of the 79 companies featured in this Fixed Income Assets Management market report include: This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include: Key Attributes: Key Topics Covered: MARKET OVERVIEW MARKET TRENDS & DRIVERS FOCUS ON SELECT PLAYERS For more information about this report visit https://www.researchandmarkets.com/r/u61101 About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Dublin, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The "United States Foodservice Market Report by Sector, System, Type of Restaurant, States and Company Analysis 2025-2033" report has been added to ... Dublin, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The "United States Adult Vaccine Market Report by Disease wise - Adult Vaccines Market, Disease wise - Numbers of Vaccinated Adults, States and Company...
--------------------------------------------------